BioSpace News Archive

Bausch + Lomb Corporation announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023.

Microbiotica today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, announced that management will attend the following conferences in the upcoming weeks.

ImaginAb Inc. is pleased to announce the execution of a new non-exclusive License and Supply Agreement with Leucid Bio, a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell therapies using the Company’s proprietary Lateral CAR Platform.

Aspect Biosystems and Novo Nordisk A/S announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2023 financial results on Thursday, April 20, 2023, after market close.

Glaukos Corporation plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023.

Canopy Biosciences, a Bruker Company, and Enable Medicine, today announced a partnership to provide Enable Medicine’s advanced analysis pipelines for spatial omics data with the Canopy CellScape ™ system for quantitative high-plex spatial biology.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023.

Cybin Inc. today announced the launch of EMBARK Open Access (“EMBARK OA”), a free online foundational training course for psychedelic facilitation.